Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degeneration

Novartis

Status and phase: Completed; Phase 1

Conditions: Wet Age-Related Macular Degeneration

Treatments: Drug: ACZ885

Study type: Interventional

Funder types: Industry

Identifiers

NCT00503022

CACZ885F2201

Details and patient eligibility

About

This study evaluates the tolerability and safety of a single intravenous infusion of ACZ885. It also explores the efficacy of the compound in central macular edema and visual acuity in patients with wet age-related macular edema.

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female ≥ 50 years old, with aged related macular degeneration
• Patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration

Exclusion criteria

• Active intraocular inflammation or ocular infection in the study eye
• Eye disease that may result in visual loss during the study
• Chronic therapy with topical, local or systemic corticosteroids.
• Pregnant or nursing (lactating) women.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind